Amicus Therapeutics, Inc. (NASDAQ:FOLD) CFO William D. Baird III sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total value of $147,200.00. Following the transaction, the chief financial officer now directly owns 105,121 shares in the company, valued at $1,547,381.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Amicus Therapeutics, Inc. (FOLD) opened at $16.65 on Tuesday. Amicus Therapeutics, Inc. has a 1-year low of $5.07 and a 1-year high of $17.40. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. The firm has a market capitalization of $2,770.00, a PE ratio of -9.10 and a beta of 1.72.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The firm had revenue of $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. During the same period in the prior year, the company posted ($0.33) EPS. The firm’s revenue was up 419.0% compared to the same quarter last year. equities research analysts forecast that Amicus Therapeutics, Inc. will post -1.52 EPS for the current year.

Several equities research analysts recently weighed in on FOLD shares. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. BidaskClub raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, January 15th. Zacks Investment Research raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Tuesday, October 10th. Robert W. Baird reissued an “outperform” rating and issued a $18.00 target price (up from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Finally, Cowen reissued a “buy” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 10th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $18.31.

Several large investors have recently added to or reduced their stakes in the stock. FMR LLC grew its position in shares of Amicus Therapeutics by 3.4% during the second quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock worth $215,876,000 after purchasing an additional 705,153 shares in the last quarter. Perceptive Advisors LLC grew its position in shares of Amicus Therapeutics by 3.4% during the third quarter. Perceptive Advisors LLC now owns 17,888,597 shares of the biopharmaceutical company’s stock worth $269,760,000 after purchasing an additional 591,925 shares in the last quarter. Redmile Group LLC grew its position in shares of Amicus Therapeutics by 5.9% during the second quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock worth $121,282,000 after purchasing an additional 668,080 shares in the last quarter. Jennison Associates LLC grew its position in shares of Amicus Therapeutics by 9.4% during the third quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock worth $147,362,000 after purchasing an additional 838,267 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Amicus Therapeutics by 5.0% during the second quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock worth $91,821,000 after purchasing an additional 430,486 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Amicus Therapeutics, Inc. (FOLD) CFO Sells 10,000 Shares of Stock” was posted by Marea Informative and is owned by of Marea Informative. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.mareainformativa.com/insider-selling-amicus-therapeutics-inc-fold-cfo-sells-147200-00-in-stock-updated-updated-updated/125873/.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.